InteliSwab revenue of $43.1 million in Q2, up 95% sequentially with significant scaling in production
InteliSwab gross margins improve sequentially by over 2,000 basis points
GAAP gross margin of 34.4%, a decrease of 200 basis points sequentially; non-GAAP gross margins improve 250 basis points sequentially to 40.1% despite headwinds
Q2 GAAP EPS of ($0.26) and non-GAAP EPS of ($0.00)
Company expects to generate positive cash flow in the 4Q22
Announces strategic transformation, including appointment of new Chief Financial Officer and changes in the Board of Directors to occur in November
Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET
OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its financial results for the three months ended June 30, 2022.
"This quarter we delivered strong revenue growth driven by InteliSwab which helped offset headwinds in our core business. We have commenced our strategic transformation with a three-part approach intended to strengthen our foundation, elevate our existing lines of business and accelerate growth. Our team also made significant progress in cost productivity and manufacturing efficiency priorities which we believe will lead to positive cash flow later this calendar year," said OraSure President and CEO Carrie Eglinton Manner.
She continued, "Our teams are committed to innovating and operating with disciplined execution and accountability across the organization. We see an important strategic niche for OraSure as a Company leveraging our strengths in the face of current shifts in healthcare delivery. We are dedicated to facilitating testing and sample collection for patients at the point of care. In further evolving our organization's strategic plan, we will provide updates on our progress. We are committed to driving sustained profitable growth over the long-term and to unlocking shareholder value."
Recent Business Highlights
InteliSwab COVID-19 Testing
-- InteliSwab revenue in the quarter grew to $43.1 million representing over 95% sequential growth relative to the first quarter.
Diagnostics Business Results (excluding InteliSwab)
The Company is guiding toward 3Q22 revenue of $90 to $95 million representing 67% to 76% growth relative to the third quarter of last year. The Company also anticipates continued improvements in gross margins, and improved cash flow from operations in the third quarter. As such, the Company is guiding to having positive cash flow from operations beginning in the fourth quarter of this fiscal year.
New Chief Financial Officer
OraSure has appointed Kenneth J. McGrath as the Company's new Chief Financial Officer, effective August 8, 2022. Mr. McGrath replaces Scott Gleason, who has served as the interim Chief Financial Officer and will continue in his role leading Investor Relations and Corporate Communications going forward. Mr. McGrath joined Quest Diagnostics in February 2014 and most recently served as Vice President in Finance, where he led an organization responsible for over $7 billion in revenue. He helped build Quest's Advanced Diagnostics business accelerating growth while improving profitability with expanded capabilities and new innovation. His expertise also includes value creation via partnerships and successfully assessing and integrating multiple acquisitions. Mr. McGrath's finance operating responsibility also spanned information technology, R&D and medical functions, as well as commercial regions amongst other responsibilities. Prior to his time at Quest, Mr. McGrath held various leadership positions in finance operating roles at Johnson & Johnson Inc. He began his career at Ford Motor Company, received an M.B.A from the University of Michigan and a B.S from the University of Notre Dame, and is a CFA Charterholder.
Changes to Board of Directors
On August 8, 2022, OraSure granted Ken McGrath, OraSure's newly appointed Chief Financial Officer, an inducement award of 131,883 shares of restricted stock. The restricted stock granted to Mr. McGrath will vest in three equal annual installments, on the first, second and third anniversaries of the grant date, subject in each case to Mr. McGrath's continued employment through the relevant vesting date.
In addition, on August 8, 2022, OraSure granted Zachary Wert, the Company's newly appointed Senior Vice President, Global Operations, an inducement award of 49,456 shares of restricted stock. The restricted stock granted to Mr. Wert will vest in full on August 8, 2023, subject to Mr. Wert's continued employment through that date.
The inducement awards for each of Mr. McGrath and Mr. Wert were approved by OraSure's Board of Directors, and were granted pursuant to Nasdaq Listing Rule 5635(c)(4), as an inducement material their acceptance of employment with OraSure.
Financial Data (Unaudited)
Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Results of Operations Net revenues $ 80,231 $ 57,607 $ 147,938 $ 116,189 Cost of products and services sold 52,647 26,934 96,082 47,190 Gross profit 27,584 30,673 51,856 68,999 Operating expenses: Research and development 9,068 7,682 17,481 16,674 Sales and marketing 11,684 10,420 24,401 19,950 General and administrative 17,579 10,993 36,735 21,181 Goodwill and long-lived assets impairment charges 10,542 - 10,542 - Change in fair value of acquisition-related contingent consideration - (220 ) (36 ) (1,026 ) Total operating expenses 48,873 28,875 89,123 56,779 Operating income (loss) (21,289 ) 1,798 (37,267 ) 12,220 Other income 1,318 448 1,265 329 Income (loss) before income taxes (19,971 ) 2,246 (36,002 ) 12,549 Income tax expense (1,169 ) 3,610 2,767 10,139 Net income (loss) $ (18,802 ) $ (1,364 ) $ (38,769 ) $ 2,410 Earnings (loss) per share: Basic $ (0.26 ) $ (0.02 ) $ (0.54 ) $ 0.03 Diluted $ (0.26 ) $ (0.02 ) $ (0.54 ) $ 0.03 Weighted average shares: Basic 72,496 71,983 72,361 71,931 Diluted 72,496 71,983 72,361 72,683
Three Months Ended Six Months Ended June 30, June 30, 2022 2021 %Change 2022 2021 %Change DIAGNOSTICS Infectious Disease Testing Revenues Domestic HIV $ 3,741 $ 4,135 (10 ) % $ 7,506 $ 9,050 (17 ) % International HIV 6,616 6,809 (3 ) 11,017 10,672 3 Net HIV revenues 10,357 10,944 (5 ) 18,523 19,722 (6 ) Domestic HCV 2,537 2,571 (1 ) 4,574 3,754 22 International HCV 1,154 1,729 (33 ) 2,374 2,914 (19 ) Net HCV revenues 3,691 4,300 (14 ) 6,948 6,668 4 Net OraQuick(R) revenues 14,048 15,244 (8 ) 25,471 26,390 (3 ) COVID-19 43,114 89 NM 65,250 262 NM Other infectious disease revenues 184 290 (37 ) 460 342 35 Total Infectious Disease 57,346 15,623 267 91,181 26,994 238 Risk Assessment 2,630 2,629 -- 5,191 4,591 13 Other non-product revenues 479 1,059 (55 ) 2,393 2,272 5 TOTAL DIAGNOSTIC NET REVENUE 60,455 19,311 213 98,765 33,857 192 MOLECULAR SOLUTIONS Genomics $ 15,486 $ 19,498 (21 ) $ 30,578 $ 30,316 1 Microbiome 1,832 2,447 (25 ) 3,822 4,198 (9 ) COVID-19 264 11,981 (98 ) 9,161 39,953 (77 ) Laboratory services 1,204 3,114 (61 ) 2,938 5,611 (48 ) Other product and services revenues 405 449 (10 ) 1,532 657 133 Net product and service revenues 19,191 37,489 (49 ) 48,031 80,735 (41 ) Other non-product and service revenues 585 807 (28 ) 1,142 1,597 (28 ) TOTAL MOLECULAR SOLUTIONS NET REVENUE 19,776 38,296 (48 ) 49,173 82,332 (40 ) TOTAL NET REVENUES $ 80,231 $ 57,607 39 % $ 147,938 $ 116,189 27 %
Condensed Consolidated Balance Sheets (Unaudited) June 30, 2022 December 31, 2021 Assets Cash and cash equivalents $ 66,159 $ 116,762 Short-term investments 29,625 36,279 Accounts receivable, net 62,886 45,323 Inventories 71,304 53,138 Other current assets 37,332 36,929 Property, plant and equipment, net 93,697 88,164 Intangible assets, net 12,851 14,343 Goodwill 36,038 40,279 Long-term investments - 17,009 Other noncurrent assets 19,362 12,764 Total assets $ 429,254 $ 460,990 Liabilities and Stockholders' Equity Accounts payable $ 36,226 $ 28,024 Deferred revenue 2,660 2,936 Other current liabilities 26,600 37,104 Other non-current liabilities 19,576 12,393 Stockholders' equity 344,192 380,533 Total liabilities and stockholders' equity $ 429,254 $ 460,990
Additional Financial Data (Unaudited) Six Months Ended June 30, 2022 2021 Capital expenditures $ 25,281 $ 22,929 Depreciation and amortization $ 7,777 $ 5,524 Stock-based compensation $ 6,804 $ 2,937 Cash used in operating activities $ 45,489 $ 3,472
The Company will host a conference call and audio webcast for analysts and investors to discuss the Company's second quarter 2022 results and certain business developments, beginning today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). On the call will be Carrie Eglinton Manner, President and Chief Executive Officer, Lisa Nibauer, President Diagnostics, Kathleen Weber, President Molecular Solutions, Ken McGrath, Chief Financial Officer, and Scott Gleason, SVP Investor Relations and Corporate Communications. The call will include prepared remarks by management and a question and answer session.
In order to listen to the conference call, please dial (866) 374-5140 and reference Conference ID #11565698 or go to OraSure Technologies' web site, www.orasure.com, and click on the Investor Relations page. Please click on the webcast link and follow the prompts for registration and access 10 minutes prior to the call. A replay of the call will be archived on OraSure Technologies' web site shortly after the call has ended and will be available for 14 days. It is recommended to dial-in 15 to 20 minutes prior to the call start to reduce waiting times. If a participant will be listen-only, they are encouraged to listen via the webcast on OraSure's Investor Relations page.
OraSure has received Emergency Use Authorizations (EUA) from the FDA for its InteliSwab COVID-19 rapid tests. The FDA has authorized the InteliSwab COVID-19 Rapid Test for Over-the-Counter (OTC) use without a prescription. The FDA has also authorized the InteliSwab COVID-19 Rapid Test Pro for professional use in point of care (POC) CLIA-waived settings, and the InteliSwab COVID-19 Rapid Test Rx for Prescription Home Use. These remarkably simple COVID-19 lateral flow tests use samples self-collected from the lower nostrils. InteliSwab's unique design incorporates a built-in swab fully integrated into the test stick. After users swab their lower nostrils, the test stick is swirled in a pre-measured buffer solution, and the result appears right on the test stick within 30 minutes, with no instruments, batteries, smartphone or laboratory analysis needed to see the result. With less than one minute of "hands-on time," it is as simple as "Swab, Swirl, and See."
This product has not been FDA cleared or approved, but it has been authorized by the FDA under an EUA. The emergency use of this product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. Â§ 360bbb- 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
Multiple government agencies, including the U.S. Department of Defense (DoD) and Department of Health and Human Services (HHS) are working to address COVID-19 testing needs. Development of the InteliSwab COVID-19 Rapid Test has been funded in whole or in part with federal funds from the HHS; the Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract numbers 75A50120C00061 and 75A50121C00078, utilizing Health Care Enhancement Act (HCEA) funding. The DoD's Defense Assisted Acquisition (DA2) Cell led the manufacturing expansion effort for the InteliSwab COVID-19 rapid test in coordination with the Department of the Air Force's Acquisition COVID-19 Task Force (DAF ACT). The manufacturing effort was funded through the American Rescue Plan Act (ARPA) to enable and support domestic industrial base expansion for critical medical resources.
About OraSure Technologies
OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure's portfolio of products is sold globally to clinical laboratories, hospitals, physician's offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.
This press release contains certain forward-looking statements, including with respect to products, product development activities, regulatory submissions and authorizations, revenue growth, cost savings, cash flow, increasing margins and other matters. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: our ability to satisfy customer demand; ability to reduce our spending rate, capitalize on manufacturing efficiencies and drive profitable growth; ability to market and sell products, whether through our internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the U.S. Food and Drug Administration ("FDA") or other regulators; the impact of the novel coronavirus ("COVID-19") pandemic on the Company's business, supply chain, labor force, ability to successfully develop new products, validate the expanded use of existing collector products, receive necessary regulatory approvals and authorizations and commercialize such products for COVID-19 testing, and demand for our COVID-19 testing products; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; ability to meet increased demand for the Company's products; impact of replacing distributors; inventory levels at distributors and other customers; ability of the Company to achieve its financial and strategic objectives and continue to increase its revenues, including the ability to expand international sales and the ability to continue to reduce costs; impact of competitors, competing products and technology changes; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid or urine testing, collection or other products; market acceptance and uptake of microbiome informatics, microbial genetics technology and related analytics services; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention ("CDC") or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; impact of contracting with the U.S. government; impact of negative economic conditions; ability to maintain sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of the Company's stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks, civil unrest, hostilities and war; and general political, business and economic conditions, including inflationary pressures. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2021, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.
Statement Regarding Use of Non-GAAP Financial Measures
In this press release, the company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures, including non-GAAP gross margin, non-GAAP operating loss, and non-GAAP earnings (loss) per share. Management believes that presentation of operating results using these non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the company's core operating results and comparison of operating results across reporting periods, while excluding certain expenses that may not be indicative of the Company's recurring core business operating results. In addition, management believes these non-GAAP financial measures are useful to investors both because they (1) allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) are used by OraSure's institutional investors and the analysis community to help them analyze the health of OraSure's business. Management also uses non-GAAP financial measures to establish budgets and to manage the company's business. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the schedules below and a description of the adjustments made to the GAAP financial measures is included at the end of the schedules.
The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Further, non-GAAP financial measures, even if similarly titled, may not be calculated in the same manner by all companies, and therefore should not be compared.
OraSure Technologies GAAP to Non-GAAP Reconciliation ($ in 000's) Three Months Ended Three Months Ended Three Months Ended Three Months Ended Mar 31, June 30, Mar 31, June 30, 2022 2022 2021 2021 Revenue $ 67,707 $ 80,231 $ 58,582 $ 57,607 GAAP Cost of Goods Sold 43,435 52,647 20,256 26,934 GAAP Gross Margin 36 % 34 % 65 % 53 % Stock compensation 150 155 62 72 Amortization of acquisition-related intangible assets 132 132 132 132 Transformation related expenses 371 544 - - Inventory reserve for excess levels 575 3,794 - - Non-GAAP Cost of Goods Sold 42,207 48,022 20,062 26,730 Non-GAAP Gross Margin 38 % 40 % 66 % 54 % GAAP Operating Income (Loss) (15,978 ) (21,289 ) 10,422 1,798 Stock compensation 2,062 2,447 1,464 1,474 Amortization of acquisition-related intangible assets 501 501 705 718 Inventory reserve for excess levels 575 3,794 - - Goodwill and long-lived assets impairment charges - 10,542 - - Transformation related expenses 4,153 902 - - Severance expense 1,461 1,531 - - Strategic alternative costs 651 197 - - Change in fair value of acquisition-related contingent consideration (36 ) - (806 ) (220 ) Non-GAAP Operating Income (Loss) (6,611 ) (1,375 ) 11,785 3,770 GAAP Net Income (Loss) (19,967 ) (18,802 ) 3,774 (1,364 ) Stock compensation 2,062 2,447 1,464 1,474 Amortization of acquisition-related intangible assets 501 501 705 718 Inventory reserve for excess levels 575 3,794 - - Goodwill and long-lived assets impairment charges - 10,542 - - Transformation related expenses 4,153 902 - - Severance expense 1,461 1,531 - - Strategic alternative costs 651 197 - - Change in fair value of acquisition-related contingent consideration (36 ) - (806 ) (220 ) Tax effect of Non-GAAP adjustments (89 ) (1,156 ) (80 ) 21 Non-GAAP Net Income (Loss) $ (10,689 ) $ (44 ) $ 5,057 $ 629 GAAP Earnings (Loss) Per Share: ($0.28 ) ($0.26 ) $0.05 ($0.02 ) Non-GAAP Earnings (Loss) Per Share: ($0.15 ) ($0.00 ) $0.07 $0.01 Diluted Shares Outstanding 72,194 72,496 72,766 71,983
Following is a description of the adjustments made to GAAP financial measures:
-- Change in fair value of acquisition-related contingent consideration: changes in the fair value of contingent consideration liability associated with estimate changes in reaching contingent consideration metrics.
Investor Contact: Media Contact: Scott Gleason Amy Koch SVP Investor Relations & Corp. Communications Sr. Mgr. Corporate Communications 484-425-0588 484-523-1815 email@example.com firstname.lastname@example.org